NEWS

Impulse Dynamics Completes $45 million Financing Round

Stuttgart, May 11, 2017 – Impulse Dynamics, developer of the revolutionary Cardiac Contractility Modulation (CCM) technology for treatment of Chronic Heart Failure (CHF), announced today that the company has closed a $45 million financing round.

The equity financing round was led by Goldstone Investment, a global investment company belonging to the Chinese conglomerate CITIC Securities, and included several other international investment firms. “We believe that CCM addresses a significant unmet need in the Chronic Heart Failure treatment paradigm,” said Mr. Ray Yang, Investment Vice President at Goldstone Investment. “We look forward to seeing Impulse realize its potential of helping millions of patients globally who currently cannot get symptom relief with existing device therapies.”

CCM is delivered by the implantable Optimizer device that administers non-excitatory electric pulses to the heart muscle, initiating multiple biochemical and neurohormonal changes to the myocardium. As a result, the contractility of the myocardium increases with no concomitant increase in oxygen consumption, enabling the heart to work more efficiently. It has already been successfully launched in Europe and is available in cardiology centers in a number of countries. CCM therapy has been implanted in over 3,500 patients to date and is available for patients with narrow QRS complex.

“We are delighted to welcome Goldstone Investment as investors in the Company,” said Dr. Simos Kedikoglou, Chief Executive Officer of Impulse Dynamics. “This investment is a significant milestone for Impulse Dynamics, and will support our continued product development efforts and market expansion globally.”

About the Optimizer and CCM Therapy
CCM is the brand name for Cardiac Contractility Modulation, the non-excitatory electrical pulses delivered by the implantable Optimizer device during the absolute refractory period of the heart’s cardiac cycle to improve systolic contraction of the heart. The Optimizer System has been implanted in over 4,000 patients and is currently available in the US, Europe, China, Brazil, India, and more than 40 other countries around the world. Impulse Dynamics has completed numerous clinical studies, including several randomized controlled trials, and the results have been published in over 80 articles appearing in leading medical journals.

 

About Impulse Dynamics
Impulse Dynamics is a medical device company dedicated to transforming the treatment of chronic heart failure. With global headquarters in Mount Laurel, N.J., the company has additional offices in; Stuttgart, Germany, Orangeburg, N.Y. and Curacao For more information please visit www.impulse-dynamics.com.

Impulse Dynamics (USA), Inc.
523 Fellowship Road, Suite 203
Mt. Laurel, NJ 08054

MARKETING OPERATIONS: 

Rohan More
Global Vice President, Marketing
Impulse Dynamics
rmore@impulsedynamics.com
856-642-9933

PUBLIC RELATIONS:  

Ian Segal
Manager, Public Relations
Impulse Dynamics
isegal@impulsedynamics.com
856-642-9933

© 2023 Impulse Dynamics  Nutzungsbedingungen | Datenschutz | Impressum